Treatment for neovascular age-related macular degeneration in Sweden : outcomes at seven years in the Swedish Macula Register
Westborg, Inger ; Granstam, Elisabet ; Rosso, Aldana LU
; Albrecht, Susanne
; Karlsson, Niklas
and Lövestam-Adrian, Monica
LU
(2017)
In Acta Ophthalmologica
95(8).
p.787-795
- Abstract
PURPOSE: To present Swedish Macula Register (SMR) data regarding treatment of neovascular age-related macular degeneration (AMD) in clinical practice since 2008.
METHODS: A retrospective register-based study was conducted. Evaluation of baseline demographics, visual outcome and number of injections during this period is presented.
RESULTS: Mean age at diagnosis was 79 ± (SD) 8 years; 65% were female. The proportion of patients with <2 months' duration of symptoms increased from 26% in 2008 to 41% in 2014 (p = 0.001). Mean visual acuity (VA) at baseline increased from 54.3 ± 15.0 early treatment diabetic retinopathy study (ETDRS) letters in 2008 to 57.8 ± 15.6 letters in 2014 (CI95 2.6; 4.3; p < 0.001). Mean VA after 1... (More)
PURPOSE: To present Swedish Macula Register (SMR) data regarding treatment of neovascular age-related macular degeneration (AMD) in clinical practice since 2008.
METHODS: A retrospective register-based study was conducted. Evaluation of baseline demographics, visual outcome and number of injections during this period is presented.
RESULTS: Mean age at diagnosis was 79 ± (SD) 8 years; 65% were female. The proportion of patients with <2 months' duration of symptoms increased from 26% in 2008 to 41% in 2014 (p = 0.001). Mean visual acuity (VA) at baseline increased from 54.3 ± 15.0 early treatment diabetic retinopathy study (ETDRS) letters in 2008 to 57.8 ± 15.6 letters in 2014 (CI95 2.6; 4.3; p < 0.001). Mean VA after 1 year of treatment increased from 57.8 ± 17.7 ETDRS letters for patients who started the treatment in 2008 to 62.8 ± 16.4 ETDRS letters in patients starting treatment in 2014 (CI95 2.67; 4.64; p < 0.001). During all study years, the proportion of patients with an improvement in VA of between 5 and 15 letters was around 30%, while 14% had VA improvement of more than 15 letters. The mean number of injections during the first treatment year increased from 4.3 ± 1.9 in 2008 to 5.9 ± 2.9 in 2014 (CI95 1.40; 1.67; p < 0.001). Seven-year follow-up of 322 eyes showed a mean change of -1 letters from baseline, with a mean of 21 injections for the entire period.
CONCLUSION: The duration of symptoms before treatment decreased, while VA at baseline and after 1 year of treatment increased over the years and so did the number of injections. Long-term follow-up demonstrated stable VA.
(Less)
- author
- Westborg, Inger
; Granstam, Elisabet
; Rosso, Aldana
LU
; Albrecht, Susanne
; Karlsson, Niklas
and Lövestam-Adrian, Monica
LU
- organization
- publishing date
- 2017-08-21
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Acta Ophthalmologica
- volume
- 95
- issue
- 8
- pages
- 787 - 795
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000417645900022
- scopus:85037721307
- pmid:28834299
- ISSN
- 1755-3768
- DOI
- 10.1111/aos.13539
- language
- English
- LU publication?
- yes
- id
- 27ea5742-1a0b-4883-8d39-5ece9e9e5148
- date added to LUP
- 2017-11-21 15:52:24
- date last changed
- 2025-03-04 04:54:10
@article{27ea5742-1a0b-4883-8d39-5ece9e9e5148,
abstract = {{<p>PURPOSE: To present Swedish Macula Register (SMR) data regarding treatment of neovascular age-related macular degeneration (AMD) in clinical practice since 2008.</p><p>METHODS: A retrospective register-based study was conducted. Evaluation of baseline demographics, visual outcome and number of injections during this period is presented.</p><p>RESULTS: Mean age at diagnosis was 79 ± (SD) 8 years; 65% were female. The proportion of patients with <2 months' duration of symptoms increased from 26% in 2008 to 41% in 2014 (p = 0.001). Mean visual acuity (VA) at baseline increased from 54.3 ± 15.0 early treatment diabetic retinopathy study (ETDRS) letters in 2008 to 57.8 ± 15.6 letters in 2014 (CI95 2.6; 4.3; p < 0.001). Mean VA after 1 year of treatment increased from 57.8 ± 17.7 ETDRS letters for patients who started the treatment in 2008 to 62.8 ± 16.4 ETDRS letters in patients starting treatment in 2014 (CI95 2.67; 4.64; p < 0.001). During all study years, the proportion of patients with an improvement in VA of between 5 and 15 letters was around 30%, while 14% had VA improvement of more than 15 letters. The mean number of injections during the first treatment year increased from 4.3 ± 1.9 in 2008 to 5.9 ± 2.9 in 2014 (CI95 1.40; 1.67; p < 0.001). Seven-year follow-up of 322 eyes showed a mean change of -1 letters from baseline, with a mean of 21 injections for the entire period.</p><p>CONCLUSION: The duration of symptoms before treatment decreased, while VA at baseline and after 1 year of treatment increased over the years and so did the number of injections. Long-term follow-up demonstrated stable VA.</p>}},
author = {{Westborg, Inger and Granstam, Elisabet and Rosso, Aldana and Albrecht, Susanne and Karlsson, Niklas and Lövestam-Adrian, Monica}},
issn = {{1755-3768}},
language = {{eng}},
month = {{08}},
number = {{8}},
pages = {{787--795}},
publisher = {{Wiley-Blackwell}},
series = {{Acta Ophthalmologica}},
title = {{Treatment for neovascular age-related macular degeneration in Sweden : outcomes at seven years in the Swedish Macula Register}},
url = {{http://dx.doi.org/10.1111/aos.13539}},
doi = {{10.1111/aos.13539}},
volume = {{95}},
year = {{2017}},
}